Literature DB >> 21369830

Unique evolution characteristics of the envelope protein of EIAV(LN₄₀), a virulent strain of equine infectious anemia virus.

Xuefeng Wang1, Shuai Wang, Yuezhi Lin, Chenggang Jiang, Jian Ma, Liping Zhao, Xiaoling Lv, Fenglong Wang, Rongxian Shen, Jianhua Zhou.   

Abstract

The Chinese equine infectious anemia virus (EIAV) virulent strain EIAV(LN40) is derived from a naturally occurring virus by continuously passing in horses for 16 generations. Its genome sequence is 23% different from that of the American strains or the Japanese strains, and the variation of envelope gp90 surface unit (SU) is as high as 41%. In this study, evolutions of the EIAV(LN40) gp90 gene in four infected horses were analyzed. Results showed that new quasispecies arose in the early stage of infection in all EIAV(LN40)-infected horses. These quasispecies belonged to branches different from EIAV(LN40) in a phylogenetic tree. In contrast, the gp90 sequences of viruses isolated after disease onset remained in the same phylogenetic branch as EIAV(LN40), with some having exactly the same sequences. The glycosylation sites 191NSSN and 237NNTW in the V3 and V4 region present or absent simultaneously in most of the predicted amino acid sequences. Changes in the glycosylation sites within V3, V4, and V5 regions are usually associated with the disease status. Glycosylation sites (191NSSN, 237NNTW, and 280NDTS) within these three regions were present in EIAV(LN40) and most of the quasispecies isolated after, but not before disease onset. These unique evolutionary characteristics of SU have not been reported for EIAV and other lentiviruses. Our results provide a reference for a further understanding of the mechanism underlying the persistent infection and escape from immune surveillance of EIAV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21369830     DOI: 10.1007/s11262-010-0563-7

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  51 in total

1.  Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony.

Authors:  M Belshan; P Baccam; J L Oaks; B A Sponseller; S C Murphy; J Cornette; S Carpenter
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

2.  Genetic variation in the long terminal repeat associated with the transition of Chinese equine infectious anemia virus from virulence to avirulence.

Authors:  Lili Wei; Xiujuan Fan; Xiaoling Lu; Liping Zhao; Wenhua Xiang; Xiaoyan Zhang; Fei Xue; Yiming Shao; Rongxian Shen; Xiaojun Wang
Journal:  Virus Genes       Date:  2009-01-07       Impact factor: 2.332

3.  Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.

Authors:  C Leroux; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Characterization of infectious molecular clones of equine infectious anaemia virus.

Authors:  S L Payne; J Rausch; K Rushlow; R C Montelaro; C Issel; M Flaherty; S Perry; D Sellon; F Fuller
Journal:  J Gen Virol       Date:  1994-02       Impact factor: 3.891

5.  Characterization of the equine infectious anaemia virus S2 protein.

Authors:  Soonsang Yoon; Susan M Kingsman; Alan J Kingsman; Stuart A Wilson; Kyriacos A Mitrophanous
Journal:  J Gen Virol       Date:  2000-09       Impact factor: 3.891

6.  Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype.

Authors:  C L Kuiken; J J de Jong; E Baan; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

7.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

8.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

9.  Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.

Authors:  Laryssa Howe; Caroline Leroux; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 10.  Virus glycosylation: role in virulence and immune interactions.

Authors:  David J Vigerust; Virginia L Shepherd
Journal:  Trends Microbiol       Date:  2007-03-29       Impact factor: 17.079

View more
  4 in total

Review 1.  Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45.

Authors:  Liangwei Duan; Jiansen Du; Xinqi Liu
Journal:  Protein Sci       Date:  2015-09-21       Impact factor: 6.725

2.  Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.

Authors:  Xiue Han; Ping Zhang; Wei Yu; Wenhua Xiang; Xiaodong Li
Journal:  Virus Genes       Date:  2016-08-29       Impact factor: 2.332

3.  A unique evolution of the s2 gene of equine infectious anemia virus in hosts correlated with particular infection statuses.

Authors:  Xue-Feng Wang; Shuai Wang; Qiang Liu; Yue-Zhi Lin; Cheng Du; Yan-Dong Tang; Lei Na; Xiaojun Wang; Jian-Hua Zhou
Journal:  Viruses       Date:  2014-11-10       Impact factor: 5.048

4.  Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies In Vitro and In Vivo.

Authors:  Xue-Feng Wang; Qiang Liu; Yu-Hong Wang; Shuai Wang; Jie Chen; Yue-Zhi Lin; Jian Ma; Jian-Hua Zhou; Xiaojun Wang
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.